(Q35583358)

9 August 2017

1 reference

title

A review of imiquimod 5% cream for the treatment of various dermatological conditions (English)

1 reference

9 August 2017

1 reference

https://api.crossref.org/works/10.1046/J.1365-2230.28.S1.1.X

1 April 2024

author name string

S. Salasche

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14616801

1 April 2024

S. Shumack

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14616801

1 April 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14616801

1 April 2024

publication date

1 November 2003

1 reference

full work available at URL

9 August 2017

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1046%2Fj.1365-2230.28.s1.1.x

1 reference

https://api.crossref.org/works/10.1046/J.1365-2230.28.S1.1.X

http://onlinelibrary.wiley.com/wol1/doi/10.1046/j.1365-2230.28.s1.1.x/fullpdf

1 April 2024

1 reference

https://api.crossref.org/works/10.1046/J.1365-2230.28.S1.1.X

Clinical and Experimental Dermatology

1 April 2024

published in

1 reference

9 August 2017

volume

28 Suppl 1

1 reference

9 August 2017

page(s)

1-3

1 reference

Review Article Imiquimod applied topically: a novel immune response modifier and new class of drug

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.28.S1.1.X

Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.28.S1.1.X

Pattern recognition receptors: doubling up for the innate immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.28.S1.1.X

Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.28.S1.1.X

Immunological events in regressing genital warts

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.28.S1.1.X

A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.28.S1.1.X

European course on HPV associated pathology: guidelines for primary care physicians for the diagnosis and management of anogenital warts

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.28.S1.1.X

Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.28.S1.1.X

Imiquimod 5% cream is a safe and effective self-applied treatment for anogenital warts--results of an open-label, multicentre Phase IIIB trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.28.S1.1.X

Imiquimod 5% cream in the treatment of anogenital warts in female patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.28.S1.1.X

Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.28.S1.1.X

Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.28.S1.1.X

Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.28.S1.1.X

A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.28.S1.1.X

Cycle therapy of actinic keratoses of the face and scalp with 5% topical imiquimod cream: An open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.28.S1.1.X

Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463

21 January 2018

2

1 reference

https://api.crossref.org/works/10.1046/J.1365-2230.28.S1.1.X

Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod

1 April 2024

3

1 reference

https://api.crossref.org/works/10.1046/J.1365-2230.28.S1.1.X

Enhancement of the innate and cellular immune response in patients with genital warts treated with topical imiquimod cream 5%

1 April 2024

8

1 reference

https://api.crossref.org/works/10.1046/J.1365-2230.28.S1.1.X

Sexually transmitted diseases treatment guidelines

1 April 2024

10

1 reference

https://api.crossref.org/works/10.1046/J.1365-2230.28.S1.1.X

Safety and efficacy of imiquimod 5% cream in the treatment of penile genital warts in uncircumcised men when applied three times weekly or once per day.

1 April 2024

13

1 reference

https://api.crossref.org/works/10.1046/J.1365-2230.28.S1.1.X

Self-administered topical 5% imiquimod for the treatment of common warts and molluscum contagiosum

1 April 2024

21

1 reference

https://api.crossref.org/works/10.1046/J.1365-2230.28.S1.1.X

1 April 2024

Identifiers

1 reference

9 August 2017

1 reference